Immunobiology and the Future of Myoblast Transfer Therapy

Molecular Therapy

Volumn 1, Issue 4, 2000, Pages 304-313

  Smythe, Gayle M ^a   Hodgetts, Stuart I ^a   Grounds, Miranda D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Duchenne muscular dystrophy; Immunology; Immunosuppression; Inflammatory cells; Myoblast transfer therapy; Tissue culture

Indexed keywords

ANIMALIA;

CYTOKINE; DYSTROPHIN;

ANIMAL; CELL SURVIVAL; CULTURE TECHNIQUE; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; METHODOLOGY; PATHOLOGY; REVIEW; SKELETAL MUSCLE; STEM CELL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; CELL SURVIVAL; CULTURE TECHNIQUES; CYTOKINES; DYSTROPHIN; GENE EXPRESSION; GENE THERAPY; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; STEM CELL TRANSPLANTATION; STEM CELLS; T-LYMPHOCYTES;

EID: 0034170282     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0049     Document Type: Review

References (120)

1. Hoffman E. P., Brown R. H., Kunkel L. M. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell. 51:1987;919-928.
2. Beauchamp J., Morgan J., Pagel C., Partridge T. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J. Cell Biol. 144:1999;1113-1122.
3. Beauchamp J. R., Pagel C. N., Partridge T. A. A dual-marker system for quantitative studies of myoblast transplantation in the mouse. Transplantation. 63:1997;1794-1797.
4. Fan Y., Maley M., Beilharz M., Grounds M. Rapid death of injected myoblasts in myoblast transfer therapy. Muscle Nerve. 19:1996;853-860.
5. Qu Z., Balkir L., van Deutekom J., Robbins P., Pruchnic R., Huard J. Development of approaches to improve cell survival in myoblast transfer therapy. J. Cell Biol. 142:1998;1257-1267.
6. Rando T., Pavlath G., Blau H. The fate of myoblasts following transplantation into mature muscle. Exp. Cell Res. 220:1995;383-389.
7. + cells. Cell Transplant. 2000.
8. Grounds M. D. Commentary on the present state of knowledge for myoblast transfer therapy. Cell Transplant. 5:1996;431-433.
9. Gabe S., Bjarnson I., Tolou-Ghamari Z., Tredger J., Johnson P., Barclay G., Williams R., Silk D. The effects of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology. 115:1998;67-74.
10. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., Shimbo T., Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 397:1999;530-534.
11. Wernig A., Irintchev A., Lange G. Functional effects of myoblast implantation into histoincompatible mice with or without immunosuppression. J. Physiol. 484:1995;493-504.
12. Irintchev A., Zweyer M., Wernig A. Cellular and molecular reactions in mouse muscles after myoblast implantation. J. Neurocytol. 24:1995;319-331.
13. Huard J., Roy R., Guerette B., Verreault S., Tremblay G., Tremblay J. P. Human myoblast transplantation in immunodeficient and immunosuppressed mice: Evidence of rejection. Muscle Nerve. 17:1994;224-234.
14. Kinoshita I., Roy R., Dugre F., Gravel C., Roy B., Goulet M., Asselin I., Tremblay J. Myoblast transplantation in monkeys: Control of immune response by FK506. J. Neuropathol. Exp. Neurol. 55:1996;687-697.
15. Carroll M. C. The role of complement and complement receptors in induction and regulation of immunity. Annu. Rev. Immunol. 16:1998;545-568.
16. Houslay M. D., Stanley K. K. Dynamic membrane-associated processes. Houslay M. D., Stanley K. K. Dynamics of Biological Membranes: Influence on Synthesis, Structure and Function. 1982;281-325 Wiley, Chichester.
17. Skuk D., Tremblay J. P. Complement deposition and cell death after myoblast transplantation. Cell Transplant. 7:1998;427-434.
18. Gasque P., Morgan B. P., Legoedec J., Chan P., Fontaine M. Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing. J. Immunol. 156:1996;3402-3411.
19. Engel A. G., Beiseker G. Complement activation in muscle fibre necrosis: Demonstration of the membrane attack complex of complement in necrotic fibres. Ann. Neurol. 12:1982;289-296.
20. Harlan D., Kirk A. The future of organ and tissue transplantation: Can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? J. Am. Med. Assoc. 282:1999;1076-1082.
21. Benichou G. Direct and indirect antigen recognition: The pathways to allograft immune rejection. Frontiers Biosci. 4:1999;476-480.
22. Gudmundsdottir H., Turka L. T cell costimulatory blockade: New therapies for transplant rejection. J. Am. Soc. Nephrol. 10:1999;1356-1365.
23. Goebels N., Michaelis D., Wekerle H., Hohlfeld R. Human myoblasts as antigen-presenting cells. J. Immunol. 149:1992;661-667.
24. Michaelis D., Goebels N., Hohlfeld R. Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am. J. Pathol. 143:1993;1142-1149.
25. Partridge T. Myoblast transplantation. Lanza R., Chick W. Yearbook of Cell and Tissue Transplantation. 1996;53-59 Kluwer Academic.
26. Labrecque C., Roy R., Tremblay J. P. Immune reactions after myoblast transplantation in mouse muscle. Transplant. Proc. 24:1992;2889-2892.
27. Hohlfeld R., Engel A. Induction of HLA-DR expression on human myoblasts with interferon-gamma. Am. J. Pathol. 136:1990;503-508.
28. Long E. Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol. 17:1999;875-904.
29. Dai Z., Lakkis F. The role of cytokines, CTLA-4 and costimulation in transplantation tolerance. Curr. Opin. Immunol. 11:1999;504-508.
30. Guerette B., Gingras M., Wood K., Roy R., Tremblay J. Immunosuppression with monoclonal antibodies and CTLA4-Ig after myoblast transplantation in mice. Transplantation. 62:1996;962-967.
31. Parker D., Greiner D., Phillips N., Appel M., Steele A., Durie F., Noelle R., Mordes J., Rossini A. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA. 92:1995;9560-9564.
32. Binnerts M. E., van Kooyk Y. How LFA-1 binds to different ligands. Immunol. Today. May:1999;240-245.
33. Guerette B., Skuk D., Celestin F., Huard C., Tardif F., Asselin I., Roy B., Goulet M., Roy R., Entman M., Tremblay J. Prevention by anti-LFA-1 of acute myoblast death following transplantation. J. Immunol. 159:1997;2522-2531.
34. Guerette B., Asselin I., Skuk D., Entman M., Tremblay J. Control of inflammatory damage by anti-LFA-1: Increased success of myoblast transplantation. Cell Transplant. 6:1997;101-107.
35. Gorospe J., Nishikawa B., Hoffman E. Pathophysiology of dystrophin deficiency: A clinical and biological enigma. Brown S., Lucy J. Dystrophin: Gene, Protein and Cell Biology. 1997;201-232 Cambridge Univ. Press, Cambridge.
36. Lundberg I., Brengman J. M., Engel A. G. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J. Neuroimmunol. 63:1995;9-16.
37. Murakami N., McLennan I. S., Nonaka I., Koishi K., Baker C., Hammond-Tooke G. Transforming growth factor beta2 is elevated in skeletal muscular disorders. Muscle Nerve. 22:1999;889-898.
38. Letterio J., Roberts A. TGF-b: A critical modulator of immune cell function. Clin. Immunol. Immunopathol. 84:1997;244-250.
39. Letterio J. J., Roberts A. B. Regulation of immune responses by TGF-b. Annu. Rev. Immunol. 16:1998;137-161.
40. Cantini M., Carraro U. Control of cell proliferation by macrophage-myoblast interactions. Basic Appl. Myol. 6:1996;485-489.
41. Miller S., Ito H., Blau H., Torti F. Tumor necrosis factor inhibits human myogenesis in vitro. Mol. Cell. Biol. 8:1998;2295-2301.
42. Goodman M. Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am. J. Physiol. 260:1991;E727-E730.
43. Zamir O., Hasselgren P., Kunkel S., Frederick J., Higashiguchi T., Fischer J. Evidence that tumour necrosis factor participates in the regulation of muscle proteolysis during sepsis. Arch. Surg. 127:1992;170.
44. Massague J. Wounding smad. Nat. Cell Biol. 1:1999;E117-E119.
45. Honda H., Kimura H., Rostami A. Demonstration and phenotypic characterization of resident macrophages in rat skeletal muscle. Immunology. 70:1990;272-277.
46. Pimorady-Esfahani A., Grounds M. D., McMenamin P. G. Macrophages and dendritic cells in normal and regenerating murine skeletal muscle. Muscle Nerve. 20:1997;158-166.
47. Nahirney P., Dow P., Ovalle W. Quantitative morphology of mast cells in skeletal muscle of normal and genetically dystrophic mice. Anat. Rec. 247:1997;341-349.
48. Arahata K., Engel A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 16:1984;193-208.
49. Emslie-Smith A., Arahata K., Engel A. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum. Pathol. 20:1989;224-231.
50. Guerette B., Asselin I., Vilquin J., Roy R., Tremblay J. Lymphocyte infiltration following allo- and xenomyoblast transplantation in mdx mice. Muscle Nerve. 18:1995;39-51.
51. Arahata K., Ishiura S., Ishiguro T., Tsukahara T., Suhara Y., Eguchi C., Ishihara T., Nonaka I., Ozawa E., Sugita H. Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature. 333:1988;861-862.
52. Spencer M., Walsh C., Dorshkind K., Rodriguez E., Tidball J. Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J. Clin. Invest. 99:1997;1-7.
53. Boulanger A., Asselin I., Roy R., Tremblay J. Role of non-major histocompatibility complex antigens in the rejection of transplanted myoblasts. Transplantation. 63:1997;893-899.
54. Zamoyska R. CD4 and CD8: Modulators of T-cell receptor recognition of antigen and of immune responses? Curr. Opin. Immunol. 10:1998;82-87.
55. Stenger S., Modlin R. L. Cytotoxic T cell responses to intracellular pathogens. Curr. Opin. Immunol. 10:1998;471-477.
56. Heemels M.-T., Pleogh H. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu. Rev. Immunol. 64:1995;463-491.
57. Hohlfeld R., Engel A. G. Lysis of myotubes by alloreactive cytotoxic T cells and natural killer cells. J. Clin. Invest. 86:1990;370-374.
58. Smythe G. M., Fan Y., Grounds M. D. Enhanced donor myoblast migration and fusion in normal and dystrophic host muscle. Muscle Nerve. 23:2000;560-574.
59. Fan Y., Grounds M., Garlepp M., Beilharz M. Increased survival, movement and fusion of myoblasts from sliced muscle grafts into skeletal muscles of T-cell depleted and tolerised dystrophic host mice. Basic Appl. Myol. 7:1997;231-240.
60. Manilay J., Sykes M. Natural killer cells and their role in graft rejection. Curr. Opin. Immunol. 10:1998;532-538.
61. Bendelac A., Rivera M., Park S.-H., Roark J. Mouse CD1-specific NK1 T cells: Development, specificity, and function. Annu. Rev. Immunol. 15:1997;535-562.
62. Auchincloss H., Sachs D. Xenogeneic transplantation. Annu. Rev. Immunol. 16:1998;433-470.
63. Gourlay W. A., Chambers W. H., Monaco A. P., Maki T. Importance of natural killer cells in the rejection of hamster skin xenografts. Transplantation. 65:1998;727-734.
64. Karlsson-Parra A., Ridderstad A., Wallgren A. C., Moller E., Ljunggren H. G., Korgsren O. Xenograft rejection of porcine islet-like cell clusters in normal and natural killer cell-depleted mice. Transplantation. 61:1996;1313-1320.
65. Umesue M., Mayumi H., Nishimura Y., Kong Y. Y., Omoto K., Murakami Y., Nomoto K. Donor-specific prolongation of rat skin graft survival induced by rat-donor cells and cyclophosphamide under coadministration of monoclonal antibodies against T cell receptor alpha beta and natural killer cells in mice. Transplantation. 61:1996;116-124.
66. Yokoyama W. M. Natural killer cell receptors. Curr. Opin. Cell Biol. 10:1998;298-305.
67. Lanier L. NK cell receptors. Annu. Rev. Immunol. 16:1998;359-393.
68. Lescaudron L., Peltekian E., Fontaine-Perus J., Paulin D., Zampieri M., Garcia L., Parrish E. Blood borne macrophages are essential for the triggering of muscle regeneration following muscle transplant. Neuromusc. Disord. 9:1999;72-80.
69. Roberston T. A., Maley M. A. L., Grounds M. D., Papadimitriou J. M. The role of macrophages in skeletal muscle regeneration with particular reference to chemotaxis. Exp. Cell Res. 207:1993;321-331.
70. + macrophages increase selectively myoblast proliferation in muscle cultures. Biochem. Biophys. Res. Commun. 235:1997;754-759.
71. Cantini M., Massimino M. L., Rapizzi E., Libera L. D., Catani C., Carraro U. Viability of myoblast-macrophage cocultures. Basic Appl. Myol. 4:1994;403-406.
72. Cantini M., Massimino M. L., Bruson A., Catani C., Dalla Libera L., Carraro U. Macrophages regulate proliferation and differentiation of satellite cells. Biochem. Biophys. Res. Commun. 202:1994;1688-1696.
73. Shen Z., Reznikoff G., Dranoff G., Rock K. L. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158:1997;2723-2730.
74. +-dependent mechanism. J. Exp. Med. 186:1997;467-472.
75. Mitchell D. A., Nair S. K., Gilboa E. Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. Eur. J. Immunol. 28:1998;1923-1933.
76. Lefaucheur J.-P., Gjata B., Sebille A. Factors affecting mast cell accumulation in skeletal muscle. Neuropathol. Appl. Neurobiol. 22:1996;248-255.
77. Gorospe J. R. M., Nishikawa B. K., Hoffman E. P. Recruitment of mast cells to muscle after mild damage. J. Neurol. Sci. 135:1996;10-17.
78. Gorospe J., Tharp M., Hinckley J., Kornegay J., Hoffman E. A role for mast cells in the progression of Duchenne muscular dystrophy: Correlations in dystrophin-deficient humans, dogs, and mice. J. Neurol. Sci. 122:1994;44-56.
79. Huard J., Roy R., Bouchard J.-P., Malouin F., Richards C. L., Tremblay J.-P. Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions. Transplant. Proc. 24:1992;3049-3051.
80. Fan Y., Beilharz M. W., Grounds M. D. A potential alternative strategy for myoblast transfer therapy: The use of sliced muscle grafts. Cell Transplant. 5:1996;421-433.
81. Swift S. M., Clayton H. A., London N. J. M., James R. F. L. The potential contribution of rejection to survival of transplanted human islets. Cell Transplant. 7:1998;599-606.
82. Ostrowska A., Karrer F., Bilir B. Histological identification of purified and cryopreserved allogeneic hepatocytes following transplantation in a murine model without host immunosuppression. Transplant Int. 12:1999;188-194.
83. van Schilfgaarde R., de Vos P. Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets. J. Mol. Med. 77:1999;199-205.
84. Rando T., Blau H. M. Primary mouse myoblast purification, characterization and transplantation for cell-mediated gene therapy. J. Cell Biol. 125:1994;1275-1287.
85. Irintchev A., Langer M., Zweyer M., Wernig A. Myoblast transplantation in the mouse: What cells do we use? Basic Appl. Myol. 7:1997;161-166.
86. Smythe G. M., Grounds M. D. Exposure to tissue culture conditions adversely affects myoblasts in whole muscle grafts in vivo: Implications for myoblast transfer therapy. Cell Transplant. 9:2000.
87. Burkin D. J., Kaufman S. J. The alpha 7 beta 1 integrin in muscle development and disease. Cell Tiss. Res. 296:1999;183-190.
88. Tomatis D., Echtermayer F., Schober S., Balzac F., Retta S. F., Silengo L., Tarone G. The muscle-specific laminin receptor a7b integrin negatively regulates a5b1 fibronectin receptor function. Exp. Cell Res. 246:1999;421-432.
89. Grounds M. D., McGeachie J. K., Davies M. J., Sorokin L., Maley M. A. L. The expression of extracellular matrix during adult skeletal muscle regeneration: How the basement membrane, interstitium, and myogenic cells collaborate. Basic Appl. Myol. 8:1998;129-142.
90. Ringlemann B., Roder C., Hallmann R., Maley M., Davies M., Grounds M., Sorokin L. Expression of laminin a1, a2, a4 and a5 chains, fibronectin and tenascin-C in skeletal muscle of dystrophic 129ReJ dy/dy mice. Exp. Cell Res. 246:1999;165-182.
91. Sorokin L. M., Maley M. A. L., Moch H., von der Mark H., von der Mark K., Davies M. J., McGeachie J. K., Grounds M. D. Laminin a4 and integrin a6 are upregulated in regenerating dy/dy skeletal muscle: Comparative expression of laminin and integrin isoforms in muscles regenerating after crush injury. Exp. Cell Res. 2000.
92. Strater J., Wedding U., Barth T., Koretz K., Elsing C., Moller P. Rapid onset of apoptosis in vitro follows disruption of beta 1-integrin/matrix interactions in human colonic crypt cells. Gastroenterology. 110:1996;1776-1784.
93. Frisch S., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124:1994;619-626.
94. Thomas F., Contreras J., Bilbao G., Ricordi C., Curiel D., Thomas J. Anoikis, extracellular matrix, and apoptosis factors in isolated cell transplantation. Surgery. 126:1999;299-304.
95. Watt D. J., Karasinski J., Moss J. Migration of muscle cells. Nature. 386:1994;406-407.
96. Morgan J. E., Pagel C. N., Sherrratt T., Partridge T. A. Long-term persistence and migration of myogenic cells injected into pre-irradiated muscles of mdx mice. J. Neurol. Sci. 115:1993;191-200.
97. Kinoshita I., Vilquin J.-T., Tremblay J. Pretreatment of myoblast cultures with basic fibroblast growth factor increases the efficacy of their transplantation in mdx mice. Muscle Nerve. 18:1995;834-841.
98. Kinoshita I., Vilquin J., Roy R., Tremblay J. Successive injections in mdx mice of myoblasts grown with bFGF. Neuromusc. Disord. 6:1996;187-193.
99. Grounds M. D. Factors controlling skeletal muscle regeneration in vivo. Kakulas B. A., Mastaglia F. L. Pathogenesis and Therapy of Duchenne and Becker Muscular Dystrophy. 1990;171-185 Raven Press, New York.
100. Grounds M. D., Garrett K. L., Beilharz M. W. The transcription of MyoD1 and myogenin genes in thymic cells in vivo. Exp. Cell Res. 198:1992;357-361.
101. Goldring K., Jones G. E., Watt D. J. A factor implicated in the myogenic conversion of non-muscle cells derived from the mouse dermis. Cell Transplant. 2000.
102. Pagel C. N., Morgan J. E., Gross J. G., Partridge T. A. Thymic myoid cells as a source of cells for myoblast transfer. Cell Transplant. 2000.
103. Grounds M. Commentary: Myoblast transfer therapy in the new millenium. Cell Transplant. 2000.
104. Young H. E., Wright R., Mancini M. L., Lucas P. A., Reagan C. R., Black A. C. Bioactive factors affect proliferation and phenotypic expression in progenitor and pluripotent stem cells. Wound Repair Regen. 6:1998;65-75.
105. Gussoni E., Soneoka Y., Strickland C. D., Buzney E. A., Khan M. K., Flint A. F., Kunkel L. M., Mulligan R. C. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature. 401:1999;390-394.
106. Jackson K., Mi T., Goodell M. Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc. Natl. Acad. Sci. USA. 96:1999;14482-14486.
107. Ferrari G., Cusella-De Angelis G., Coletta M., Paolucci E., Stornaiuolo A., Cossu G., Mavilio F. Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 279:1998;1528-1530.
108. Grounds M. D. Skeletal muscle precursors do not arise from bone marrow cells. Cell Tiss. Res. 234:1983;713-722.
109. Bianco P., Cossu G. Searching for the identity of mesodermal progenitors. Exp. Cell Res. 1999.
110. Gross J., Morgan J. Muscle precursor cells injected into irradiated mdx mouse muscle persist after serial injury. Muscle Nerve. 22:1999;174-185.
111. Asselin I., Tremblay M., Vilquin J.-T., Guerette B., Roy R., Tremblay J. Quantification of normal dystrophin mRNA following myoblast transplantation in mdx mice. Muscle Nerve. 18:1995;980-986.
112. Kinoshita I., Huard J., Tremblay J. P. Utilization of myoblasts from transgenic mice to evaluate the efficacy of myoblast transplantation. Muscle Nerve. 17:1994;975-980.
113. Kinoshita I., Vilquin J., Guerette B., Asselin I., Roy R., Lille S., Tremblay J. Immunosuppression with FK 506 insures good success of myoblast transplantation in mdx mice. Transplant. Proc. 26:1994;3518.
114. Ito H., Hallauer P., Hastings K., Tremblay J. Prior culture with concanavalin A increases intramuscular migration of transplanted myoblast. Muscle Nerve. 21:1998;291-297.
115. Kinoshita I., Vilquin J., Chamberlain J., Tremblay J. Transplantation of myoblasts from a transgenic mouse overexpressing dystrophin produced only a relatively small increase of dystrophin-positive membrane. Muscle Nerve. 21:1998;91-103.
116. Brussee V., Merly F., Tardif F., Tremblay J. P. Normal myoblast implantation in MDX mice prevents muscle damage by exercise. Biochem. Biophys. Res. Commun. 250:1998;321-327.
117. Vilquin J., Kinoshita I., Roy R., Tremblay J. Cyclophosphamide immunosuppression does not permit successful myoblast allotransplantation in mouse. Neuromusc. Disord. 5:1995;511-517.
118. Vilquin J.-T., Asselin I., Guerette B., Kinoshita I., Roy R., Tremblay J. P. Successful myoblast allotransplantation in MDX mice using rapamycin. Transplantation. 59:1995;422-449.
119. Kinoshita I., Vilquin J.-T., Gravel C., Roy R., Tremblay J. Myoblast allotransplantation in primates. Muscle Nerve. 18:1995;1217-1218.
120. Skuk D., Roy B., Goulet M., Tremblay J. Successful myoblast transplantation in primates depends on appropriate cell delivery and induction of regeneration in the host muscle. Exp. Neurol. 155:1999;22-30.